Single answer
Is Apellis Pharmaceuticals Inc (APLS) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.11 or 10.91%
(In 16 weeks 2 days 23 hours 47 minutes and 46 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Apellis Pharmaceuticals Inc is $33.50, which is $11.77 (54.16%) above the current price today's price.
Low target: $19.00 | High target: $52.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Apellis Pharmaceuticals Inc a commercialstage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases The companys lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy GA in agerelated macular degeneration and paroxysmal nocturnal hemoglobinuria PNH diseases It also develops EMPAVELI systemic pegcetacoplan for the treatment of cold agglutinin disease CAD and hematopoietic stem cell transplantationassociated thrombotic microangiopathy HSCTTMA in hematology C3 glomerulopathy C3G and immune complex membranoproliferative glomerulonephritis ICMPGN in nephrology and amyotrophic lateral sclerosis ALS in neurology In addition the company develops APL2006 a bispecific C3 and VEGF inhibitor for treating complementmediated disorders APL1030 a C3 inhibitor for the treatment of multiple neurodegenerative diseases and the combination of EMPAVELI and a small interfering RNA or siRNA for reducing the production of C3 proteins by the liver It has a collaboration and license agreement with Swedish Orphan Biovitrum AB publ to codevelop pegcetacoplan and a research collaboration with Beam Therapeutics Inc focused on the use of Beams base editing technology to discover new treatments for complementdriven diseases Apellis Pharmaceuticals Inc was incorporated in 2009 and is based in Waltham Massachusetts
Website: https://www.apellis.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.10. Cash flow to debt ratio: 0.40. Net profit margin: 3.25%. Inflation risk score: low (0.50/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Apellis Pharmaceuticals Inc is $64.7M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Apellis Pharmaceuticals Inc 10 years ago, but if you had invested on 2017-11-09 when the price was $14.03, you would have made a profit of $7.39 per share or 52.67%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.